Alzheimer’s disease
104 results
1 - 100
Real-world data don’t support new Alzheimer’s disease diagnostic criteria
Alzheimer’s disease - Memantine for Alzheimer’s disease
- Donepezil for Alzheimer’s disease
- Rivastigmine for Alzheimer’s disease
- Galantamine for Alzheimer’s disease
- Cholinesterase inhibitors for Alzheimer’s disease
- High-dose B vitamins in Alzheimer’s disease
- Combination therapy with cholinesterase inhibitors and memantine for Alzheimer’s disease
- Montreal Cognitive Assessment for the diagnosis of Alzheimer’s disease and other dementias
- Atypical antipsychotics for agitation and psychosis in people with Alzheimer’s disease and vascular dementia
18F‐FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)- 11C‐PIB‐PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)
- 18F PET with florbetapir for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)
- Atypical antipsychotics worsen cognition in Alzheimer’s (CATIE-AD)
- Frontotemporal lobar degeneration
- Lecanemab does not significantly improve cognition in early Alzheimer's disease, is expensive, and causes brain edema and hemorrhage in some patients
- CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)
- 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)
- Prevention of dementia by statins
- Urinary incontinence in the elderly
- Statins do not appear to impair cognition in elderly
- Aspirin, steroidal and non‐steroidal anti‐inflammatory drugs for the treatment of Alzheimer's disease
- 18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)
- Vascular cognitive impairment (VCI)
- Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)
- Latrepirdine for Alzheimer's disease
- Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia
- Antioxidants, CoQ ineffective for patients with Alzheimer disease
- Curable causes of cognitive challenges and memory disease
- Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease
- Statins for the treatment of Alzheimer's disease
- Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer's disease and vascular dementia: Cochrane systematic review
- The Rowland Universal Dementia Assessment Scale (RUDAS) for the detection of dementia in a variety of healthcare settings
- Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI)
- Parkinson's disease dementia and dementia with Lewy bodies
- Souvenaid for Alzheimer's disease
- Parkinson's disease
- Disturbances of taste
- vitamin D + calcium = placebo for cognitive decline (WHI)
- Memory complaints, mild cognitive impairment and dementia
- CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)
- Pharmacological interventions for apathy in Alzheimer's disease
- Pharmacist services for non-hospitalised patients: Cochrane systematic review
- Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia
- Reporting is limited, but amyloid-related imaging abnormalities with edema or hemorrhage are frequent in adults receiving amyloid-directed monoclonal antibodies
- Cognitive training for people with mild to moderate dementia
- Regional Cerebral Blood Flow Single Photon Emission Computed Tomography for detection of Frontotemporal dementia in people with suspected dementia
- Cholinergic medication for antipsychotic‐induced tardive dyskinesia
- Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting
- Mini‐Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI)
- Italian guideline on diagnosing and managing dementia and mild cognitive impairment in adults
- Donepezil for mild cognitive impairment
- Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia
- Down's syndrome
- Adult hydrocephalus and shunt complications
- Cognitive rehabilitation for people with mild to moderate dementia